SCHEMBL823828

SCHEMBL823828

CC(=O)c1cc(F)c(F)c(F)c1F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.43
CES1 P23141 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.41
ALDH1A1 P00352 3/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA4 P22748 2/20 0.38
HTT P42858 1/20 0.37
CRBN Q96SW2 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAOB P27338 2/20 0.36
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11358159 0.82 TSHR (0.42) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL3419470 0.82 TSHR (0.39) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL155657 0.82 KMT2A (0.41) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL10581003 0.82 SMN1; SMN2 (0.45) CES2CES1SMN1; SMN2TDP1TSHR
SCHEMBL3183654 0.82 HDAC1 (0.39) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL24436952 0.82 HSD17B1 (0.44)
SCHEMBL7651439 0.81 SMN1; SMN2 (0.40) CES2CES1SMN1; SMN2TDP1TSHR
SCHEMBL1931579 0.80 TSHR (0.38) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL22342670 0.80 CES2 (0.38) CES2CES1SMN1; SMN2TSHRALDH1A1
SCHEMBL8952179 0.80 TSHR (0.38) CES2CES1SMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119926191-B Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-06-13 CN claimed
CN-119926191-A Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-05-06 CN claimed
CN-119409630-A Asymmetric polyfluoro-substituted 2,4' -biquinoline-4-amide derivative and preparation method and application thereof 郑州工业应用技术学院 2025-02-11 CN claimed
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN claimed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN claimed
US-8952083-B2 Fluorocopolymer composition and its production process ASAHI GLASS COMPANY, LIMITED (JP) 2015-02-10 US claimed
CN-119926191-B Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-06-13 CN disclosed
CN-119926191-A Conjugated microporous organic solvent-resistant nanofiltration composite membrane and preparation method and application thereof 中山大学 2025-05-06 CN disclosed
CN-119409630-A Asymmetric polyfluoro-substituted 2,4' -biquinoline-4-amide derivative and preparation method and application thereof 郑州工业应用技术学院 2025-02-11 CN disclosed
US-20240246968-A1 SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT MERCK SHARP & DOHME LLC 2024-07-25 US disclosed
CN-116693811-A Cationic polymer containing condensed ring structure, and preparation method and application thereof 合肥工业大学 2023-09-05 CN disclosed
CN-114950159-B Preparation method of aromatic polymer separation membrane based on super acid catalysis 南京工业大学 2023-06-06 CN disclosed
CN-114950159-A Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation 南京工业大学 2022-08-30 CN disclosed
EP-0154780-B1 QUINOLINE ANTIBACTERIAL COMPOUNDS ABBOTT LABORATORIES (US) 1990-04-11 EP disclosed
EP-0298020-A1 Use of an epoxidation reagent, and process for the preparation of 5-alpha (10-alpha) epoxy-delta 9(11) steroids SCHERING AKTIENGESELLSCHAFT (DE) 1989-01-04 EP disclosed
US-4774246-A 6,8-DIFLUORO-4-OXO-3-CARBOXYLIC ACID DERIVATIVES ABBOTT LABORATORIES (US) 1988-09-27 US disclosed
EP-0154780-A1 Quinoline antibacterial compounds ABBOTT LABORATORIES (US) 1985-09-18 EP disclosed
EP-0004315-B1 1.1-DIPHENYLETHENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MICROBICIDES CIBA-GEIGY AG (CH) 1981-02-25 EP disclosed
US-4213990-A FUNGICIDES CIBA-GEIGY CORPORATION (US) 1980-07-22 US disclosed
EP-0004315-A1 1.1-Diphenylethene derivatives, process for their preparation and their use as microbicides CIBA-GEIGY AG (CH) 1979-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246968-A1 SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT KRAS, NRAS, HRAS CES2 4855/4885CES1 4246/4885SMN1; SMN2 1620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.